OLK:NSD-Olink Holding AB ADR (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 22.84

Change

-0.23 (-1.00)%

Market Cap

USD 2.72B

Volume

0.08M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+6.81 (+1.43%)

USD 41.47B
ICLR ICON PLC

-0.60 (-0.19%)

USD 25.49B
ILMN Illumina Inc

-6.16 (-5.18%)

USD 19.47B
MEDP Medpace Holdings Inc

+1.36 (+0.34%)

USD 12.27B
NTRA Natera Inc

-0.06 (-0.06%)

USD 11.20B
EXAS EXACT Sciences Corporation

-1.94 (-3.06%)

USD 10.68B
RDNT RadNet Inc

+0.47 (+0.90%)

USD 3.57B
SHC Sotera Health Co

+0.18 (+1.59%)

USD 3.10B
NEOG Neogen Corporation

+0.27 (+2.22%)

USD 2.63B
GH Guardant Health Inc

-0.28 (-1.47%)

USD 1.96B

ETFs Containing OLK

EVNT AltShares Event-Driven ET.. 4.07 % 0.00 %

-0.02 (-0.15%)

USD 4.44M

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.18% 63% D 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.18% 63% D 38% F
Trailing 12 Months  
Capital Gain 5.89% 75% C 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.89% 75% C 58% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 0.82% 54% F 48% F
Dividend Return 0.82% 52% F 44% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 35.44% 80% B- 52% F
Risk Adjusted Return 2.31% 52% F 43% F
Market Capitalization 2.72B 83% B 84% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector